PNC-27
Kills cancer cells in a dish, never tested in a person. If you have cancer, a question for your oncologist, not a protocol.
What it is
PNC-27 is for exactly one group: people with a cancer diagnosis who have found it online and are wondering whether to inject it. The honest answer is that it punches holes in cancer cells in a petri dish, has never been tested in a human for safety or dose, and the real danger is not the peptide but what it might tempt you to delay.
Who looks at it: people with cancer, their families, and occasionally someone 'preventing' cancer with no diagnosis at all. For the last group there is nothing for it to do; it targets a marker (HDM-2 on the cell surface) that normal cells do not display, so in a healthy person it is an injection with no target. For the first group, it is the most speculative compound on this site, and the stakes of getting the decision wrong are the highest.
What it is: a 32-amino-acid peptide designed in a university lab that fuses a piece of the p53 tumor-suppressor protein with a membrane-penetrating tail. Cancer cells that express HDM-2 on their outer membrane bind the p53 piece, the tail pierces the membrane, and the cell dies by rupture (necrosis) rather than the slow programmed death most chemotherapy triggers. In cell culture it has done this to a range of cancer lines while leaving normal cells alone. That selectivity is real in a dish. 'Real in a dish' describes most cancer drug candidates that later failed.
What would you notice: nobody knows, because nobody has measured it. There is no human pharmacokinetic data, no safety study, no dose-finding, and the 100 to 500 mcg subQ once-daily numbers circulating online are not derived from any trial; they are forum consensus. A 30 mg vial at 300 mcg a day is 100 days of supply, which tells you the vendors expect long runs for a compound with no human data on long runs. People who use it report injection-site reactions and, inconsistently, flu-like days; whether any tumor changed is not something a self-run protocol can tell you.
The evidence, once: cell-culture studies showing selective necrosis of HDM-2-expressing cancer cells, and little else that we can verify. We grade it zero for animals and zero for humans, and nothing we found contradicts that. Promising mechanism, zero translation. The gap between those two is where most cancer candidates die, and it is not a gap a person should try to cross alone.
What to respect and how: if you have cancer, bring this to your oncologist as a question, in writing, with the vendor page. The thing to respect is not mainly toxicity, which is unknown, but substitution: every week spent on an untested peptide instead of a proven treatment is a week the proven treatment did not get. The alternatives this site lists next to PNC-27 are healing peptides it was filed with, not cancer tools; there is no substitute for it here, because there is no evidence-based peptide for treating cancer on this site or anywhere else yet.
What people use it for
Killing cancer cells in a dish
Early daysIn cell culture, PNC-27 binds HDM-2 on the surface of cancer cells and ruptures their membranes, killing a range of cancer cell lines by necrosis. This is the entire basis for interest in it. Cell-culture kills are the first and easiest hurdle in cancer drug development, and most compounds that clear it never make it to a patient.
Leaving healthy cells alone
Early daysNormal cells do not display HDM-2 on their surface, and in the same studies PNC-27 spared them. That selectivity is the attractive part. It has only been shown in culture, where there are no immune cells, no liver, no kidneys and no years of exposure to find out what else the membrane-piercing tail touches.
Testing in animals and people
Early daysWe could not find published animal efficacy or toxicity data we can verify, and there is no human study of any kind: no safety trial, no dose-finding, no case series. The doses used online come from forums. Every statement about what PNC-27 does in a body is a guess.
How people use it
Safety, in brief
Things people sometimes notice
- Redness, swelling or a sore bump where you inject
- Flu-like fatigue or achiness for a day, reported inconsistently by users
- Nothing systematic is known; no human side-effect profile exists
The full picture — stop signs and who should talk to a doctor first — is on the dosing guide.
Sources
The labels and studies behind this page. Each link opens the original on PubMed, DailyMed or ClinicalTrials.gov.
- Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes
- Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells
- Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia